Costeff syndrome
Overview
Costeff syndrome, also known as 3-methylglutaconic aciduria type III, is a rare inherited metabolic and neuro-ophthalmological disorder characterized by early-onset vision loss due to optic nerve degeneration, followed later by movement difficulties.
Symptoms
Vision Symptoms
• Optic atrophy: Worsening vision and loss of visual acuity starting in infancy or early childhood.
• Nystagmus: Fast, involuntary eye movements.
• Strabismus: Eyes that do not line up or look in the same direction.
Movement and Neurological Symptoms
• Chorea: Involuntary, unpredictable body movements starting in late childhood.
• Ataxia: Poor muscle control and balance issues.
• Spasticity: Stiff muscles and tight reflexes (spastic paraparesis) that can worsen over time.
• Delayed milestones: Late walking or delayed motor skill development.
• Dysarthria: Difficulty speaking clearly.
Other Signs
• Cognitive impact: Many individuals have normal intelligence, though some experience mild-to-moderate intellectual disability.
• Biochemical marker: High levels of 3-methylglutaconic acid in the urine (3-methylglutaconic aciduria).
Causes
• Gene Mutation: Changes or pathogenic variants in the OPA3 gene disrupt normal cellular and mitochondrial processes.
• Inheritance Pattern: It follows an autosomal recessive inheritance pattern. This means an affected individual must inherit one mutated copy of the gene from each parent.
• Population Prevalence: It is a rare disorder found predominantly—though not exclusively—in individuals of Iraqi-Jewish descent due to a specific founder mutation
Diagnosis
• Clinical Evaluation: Assessment for early-onset progressive optic atrophy (vision loss typically starting in early childhood), horizontal nystagmus, and extrapyramidal movement disorders like chorea developing before age ten.
• Biochemical Testing: Urine organic acid analysis showing elevated 3-methylglutaconic acid (3-methylglutaconic aciduria) and 3-methylglutaric acid.
• Molecular Genetic Testing: Single-gene testing or comprehensive panel sequencing of the OPA3 gene to detect pathogenic mutations (biallelic variants) confirming an autosomal recessive inheritance pattern
Treatment
• Visual Impairment: Evaluated and treated by an ophthalmologist, often utilizing visual aids and community vision services.
• Spasticity and Movement Disorders: Addressed with physical therapy, occupational therapy, stretching, and mobility devices (such as wheelchairs) to prevent contractures and falls.
• Feeding and Nutrition: Managed with feeding therapy for poor weight gain or swallowing difficulties.
Mitochondrial Toxins: Patients should strictly avoid tobacco, alcohol, and any medications known to impair mitochondrial function
Family Planning: Genetic counseling is recommended for affected individuals and their families because the condition is inherited in an autosomal recessive manner.
Type of Doctor Department : Ophthalmologist , Neurologist

Comments
Post a Comment